CTOs on the Move

Oncopeptides

www.oncopeptides.com

 
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

RIA International

RIA International is a East Hanover, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Groupe Parima

Groupe Parima is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rhoads Pharmacy

Rhoads Pharmacy is a Hummelstown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novopharm

Novopharm is a Scarborough, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allarity Therapeutics

Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Cambridge, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.